- $1.12bn
- $934.72m
- $239.44m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 45.15 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.05 | ||
| Price to Tang. Book | 3.36 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.29 | ||
| EV to EBITDA | 39.44 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 3.42% | ||
| Return on Equity | 1.09% | ||
| Operating Margin | 4.04% | ||
Financial Summary
| Year End 2nd Jan | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 230.47 | 284.39 | 322.42 | 313.9 | 239.44 | 334.29 | 363.42 | 7.93% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +243.15 | +62.36 | -45.95 | n/a | n/a | n/a | +100 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also markets and sells an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company's principal products are ICLs used in refractive surgery, including its EVO family of lenses.
Directors
- Louis Silverman NEC (62)
- Caren Mason PRE (67)
- Patrick Williams CFO (48)
- Hans-Martin Blickensdoerfer SVP (56)
- James Francese SVP (56)
- Graydon Hansen SVP (63)
- Keith Holliday CTO (58)
- Jon Hayashida VPR (63)
- Scott Barnes OTH (59)
- Samuel Gesten SEC (59)
- Stephen Farrell IND (56)
- Thomas Frinzi IND (65)
- Gilbert Kliman IND (62)
- Elizabeth Yeu IND (42)
- K. Peony Yu IND (58)
- Last Annual
- January 2nd, 2026
- Last Interim
- July 3rd, 2026
- Incorporated
- April 3rd, 1986
- Public Since
- February 24th, 1992
- No. of Shareholders
- 233
- No. of Employees
- 957
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 50,143,984
- Address
- 1911 Walker Ave, MONROVIA, 91016
- Web
- https://www.staar.com/
- Phone
- +1 6263037902
- Auditors
- BDO USA, LLP
Latest News for STAA
Upcoming Events for STAA
Similar to STAA
908 Devices
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
Anbio Biotechnology
NASDAQ Global Market
Anteris Technologies Global
NASDAQ Global Market
AtriCure
NASDAQ Global Market
FAQ
As of Today at 05:29 UTC, shares in STAAR Surgical are trading at $22.26. This share price information is delayed by 15 minutes.
Shares in STAAR Surgical last closed at $22.26 and the price had moved by -13.72% over the past 365 days. In terms of relative price strength the STAAR Surgical share price has underperformed the S&P500 Index by -26.14% over the past year.
The overall consensus recommendation for STAAR Surgical is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreSTAAR Surgical does not currently pay a dividend.
STAAR Surgical does not currently pay a dividend.
STAAR Surgical does not currently pay a dividend.
To buy shares in STAAR Surgical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $22.26, shares in STAAR Surgical had a market capitalisation of $1.12bn.
Here are the trading details for STAAR Surgical:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: STAA
Based on an overall assessment of its quality, value and momentum STAAR Surgical is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in STAAR Surgical is $28.00. That is 25.79% above the last closing price of $22.26.
Analysts covering STAAR Surgical currently have a consensus Earnings Per Share (EPS) forecast of $0.28 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like STAAR Surgical. Over the past six months, its share price has underperformed the S&P500 Index by -18.52%.
As of the last closing price of $22.26, shares in STAAR Surgical were trading -5.57% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The STAAR Surgical PE ratio based on its reported earnings over the past 12 months is 45.15. The shares last closed at $22.26.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
STAAR Surgical's management team is headed by:
- Louis Silverman - NEC
- Caren Mason - PRE
- Patrick Williams - CFO
- Hans-Martin Blickensdoerfer - SVP
- James Francese - SVP
- Graydon Hansen - SVP
- Keith Holliday - CTO
- Jon Hayashida - VPR
- Scott Barnes - OTH
- Samuel Gesten - SEC
- Stephen Farrell - IND
- Thomas Frinzi - IND
- Gilbert Kliman - IND
- Elizabeth Yeu - IND
- K. Peony Yu - IND